AZ ROC: CR-42 320942
title icon

2011 AACR Poster: Phase I Clinical Study of Systemic TUSC2 Nanoparticle Therapy (Oncoprex®) in Stage IV Lung Cancer Patients

A poster describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The poster was presented at the 2011 Annual Meeting of the American Association for Cancer Research (AACR) and received a Highly Rated Paper award from AACR.